Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Thrombocytosis 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Breast Neoplasms 1Blast Crisis 1Anemia 1

Interventions

Specimen Handling 1Imatinib Mesylate 1Granulocyte Colony-Stimulating Factor 1Genetic Counseling 1Filgrastim 1Decitabine 1Clinical Trials, Phase I as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × Classical hematology × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡